727.20
price down icon2.55%   -19.00
after-market 시간 외 거래: 727.00 -0.20 -0.03%
loading

Lilly Eli Co 주식(LLY)의 최신 뉴스

pulisher
07:16 AM

Cramer's Lightning Round: Eli Lilly is a buy - NBC Philadelphia

07:16 AM
pulisher
04:57 AM

Lilly pill cuts genetic form of cholesterol nearly 86% in study - Reuters.com

04:57 AM
pulisher
04:30 AM

Lilly heart drug muvalaplin significantly reduces lipoprotein(a) levels - Seeking Alpha

04:30 AM
pulisher
03:08 AM

Lilly’s muvalaplin lowered lipoprotein(a) levels in adults in Phase 2 trial - TipRanks

03:08 AM
pulisher
02:54 AM

Lilly's muvalaplin lowered lipoprotein(a) levels in adults with high risk for cardiovascular events by up to 85% at highest tested dose - Investors | Eli Lilly and Company

02:54 AM
pulisher
11:07 AM

Eli Lilly follows J&J in suing Biden administration over 340B rebates - Healthcare Dive

11:07 AM
pulisher
10:48 AM

Tesla, Eli Lilly lead market cap stock movers on Monday By Investing.com - Investing.com South Africa

10:48 AM
pulisher
10:41 AM

Revisto, Inc announced that it has received $4 million in funding from LiveOak Ventures, Eli Lilly and Company, TAU VENTURES, Arkin Digital Health - Marketscreener.com

10:41 AM
pulisher
10:04 AM

Eli Lilly's Zepbound/Mounjaro Shows Cardiovascular Benefits In Patients With Obesity-Related Heart Failure - Yahoo Finance

10:04 AM
pulisher
08:37 AM

Eli Lilly Says Phase 3 Trial of Tirzepatide Met Primary, Secondary Endpoints - Marketscreener.com

08:37 AM
pulisher
06:45 AM

Eli Lilly’s tirzepatide cuts risk of worsening heart failure in HFpEF, obese patients (NYSE:LLY) - Seeking Alpha

06:45 AM
pulisher
06:03 AM

3 Growth Stocks You Can Buy Right Now Without Any Hesitation - The Motley Fool

06:03 AM
pulisher
06:02 AM

Exclusive-Medicaid fuels US coverage of Novo, Lilly weight-loss drugs - Colorado Springs Gazette

06:02 AM
pulisher
05:36 AM

Eli Lilly: positive results for tirzepatide - Marketscreener.com

05:36 AM
pulisher
03:00 AM

Eli Lilly reports outcomes from Phase III trial of tirzepatide for HFpEF - Clinical Trials Arena

03:00 AM
pulisher
Nov 17, 2024

If You Bought 1 Share of Eli Lilly in 1984, Here's How Many Shares You Would Own Now - The Motley Fool

Nov 17, 2024
pulisher
Nov 17, 2024

Eli Lilly and Novo Want to Shake off Ozempic Copycats. Are They Ready to Meet Demand? - Yahoo! Voices

Nov 17, 2024
pulisher
Nov 16, 2024

Lilly's tirzepatide reduced the risk of worsening heart failure events by 38% in adults with heart failure with preserved ejection fraction (HFpEF) and obesity - Investors | Eli Lilly and Company

Nov 16, 2024
pulisher
Nov 15, 2024

Eli Lilly Says HHS Ignores Drug Discount Double-Dipping - Law360

Nov 15, 2024
pulisher
Nov 15, 2024

Lilly Sues U.S. to Change Hospital Drug Discount PaymentsWSJ - The Wall Street Journal

Nov 15, 2024
pulisher
Nov 15, 2024

Eli Lilly & Co. stock underperforms Friday when compared to competitors - MarketWatch

Nov 15, 2024
pulisher
Nov 15, 2024

Lilly Sues HHS for Ending Planned 340B Drug Program Cash Rebates - Bloomberg Law

Nov 15, 2024
pulisher
Nov 15, 2024

Eli Lilly sues to change hospital drug discount payments, WSJ reports - TipRanks

Nov 15, 2024
pulisher
Nov 15, 2024

Eli Lilly and Co (NYSE:LLY) Sues Federal Health Agency over Hospital Drug Discounts - TipRanks

Nov 15, 2024
pulisher
Nov 15, 2024

Eli Lilly, J&J Sue US Over Rejected Changes To Drug Discounting Program - Yahoo! Voices

Nov 15, 2024
pulisher
Nov 15, 2024

Eli Lilly: sues US federal agency - Marketscreener.com

Nov 15, 2024
pulisher
Nov 15, 2024

Lilly sues US agency over blocking of drug-rebate program - Reuters

Nov 15, 2024
pulisher
Nov 15, 2024

Should You Forget Eli Lilly and Buy This Magnificent Biotech Stock Instead? - The Motley Fool

Nov 15, 2024
pulisher
Nov 14, 2024

Lilly Statement on New 340B Litigation - Investors | Eli Lilly and Company

Nov 14, 2024
pulisher
Nov 14, 2024

ELI LILLY AND COMPANY - Marketscreener.com

Nov 14, 2024
pulisher
Nov 14, 2024

Eli Lilly & Co. stock underperforms Thursday when compared to competitors - MarketWatch

Nov 14, 2024
pulisher
Nov 14, 2024

Zepbound Cuts the Risk of Progressing to Diabetes by 94%, Eli Lilly Data Shows - Verywell Health

Nov 14, 2024
pulisher
Nov 14, 2024

99% Of Mounjaro/Zepbound Patients Remained Diabetes-Free Even At 3 Years, Eli Lilly's Detailed Phase 3 Data Shows - Benzinga

Nov 14, 2024
pulisher
Nov 14, 2024

Lilly expands research in Singapore with focus on sleep quality - Indianapolis Business Journal

Nov 14, 2024
pulisher
Nov 14, 2024

Eli Lilly Stock: Is LLY Stock A Sell After Its Disastrous Third-Quarter Report? - Investor's Business Daily

Nov 14, 2024
pulisher
Nov 14, 2024

Smart toilet, AI platform among tech in use at drugmaker Eli Lilly’s new $42m hub in S’pore - The Straits Times

Nov 14, 2024
pulisher
Nov 14, 2024

Eli Lilly: conclusive phase III trial on tirzepatide - Marketscreener.com

Nov 14, 2024
pulisher
Nov 14, 2024

Lilly reports trial results of tirzepatide for treating obesity and pre-diabetes - Clinical Trials Arena

Nov 14, 2024
pulisher
Nov 14, 2024

Lilly Expands Research in Singapore With Focus on Sleep Quality - BNN Bloomberg

Nov 14, 2024
pulisher
Nov 14, 2024

Eli Lilly's Tirzepatide Reduces Type 2 Diabetes Risk by 94% in Long-Term Study - Yahoo Finance

Nov 14, 2024
pulisher
Nov 13, 2024

Ozempic MDL Plaintiffs Say Eli Lilly, Novo Nordisk Hid Risks - Law360

Nov 13, 2024
pulisher
Nov 13, 2024

Eli Lilly Say Most Tirzepatide Users Remained Diabetes-Free at 176 Weeks - Marketscreener.com

Nov 13, 2024
pulisher
Nov 13, 2024

Eli Lilly's New Drug Shows Promise In Diabetes Prevention - Finimize

Nov 13, 2024
pulisher
Nov 13, 2024

Lilly three-year tirzepatide results show sustained weight loss, diabetes benefits - Seeking Alpha

Nov 13, 2024
pulisher
Nov 13, 2024

Treatment with tirzepatide in adults with pre-diabetes and obesity or overweight resulted in sustained weight loss and nearly 99% remained diabetes-free at 176 weeks - Investors | Eli Lilly and Company

Nov 13, 2024
pulisher
Nov 13, 2024

Eli Lilly's weight-loss drug helps nearly 99% of patients remain diabetes-free - Reuters.com

Nov 13, 2024
pulisher
Nov 13, 2024

Lilly unwraps detailed data showing tirzepatide kept nearly 99% of prediabetic patients diabetes-free over 3 years - FiercePharma

Nov 13, 2024
pulisher
Nov 13, 2024

Eli Lilly's SWOT analysis: biopharmaceutical giant's stock poised for growth - Investing.com

Nov 13, 2024
pulisher
Nov 13, 2024

Eli Lilly & Co. stock underperforms Wednesday when compared to competitors - MarketWatch

Nov 13, 2024
pulisher
Nov 13, 2024

Ex-Dividend Reminder: U.S. Physical Therapy, MMM and Eli Lilly - Nasdaq

Nov 13, 2024
pulisher
Nov 13, 2024

Why Eli Lilly’s CEO says failing faster is essential to the company’s success - Yahoo Finance

Nov 13, 2024
pulisher
Nov 13, 2024

Did Viking Therapeutics Just Say "Checkmate" To Eli Lilly? - The Motley Fool

Nov 13, 2024
pulisher
Nov 13, 2024

Humanitarian Organization Criticizes Eli Lilly, Novo Nordisk And Sanofi Of Having 'Double Standards' For High Insulin Price - Benzinga

Nov 13, 2024
pulisher
Nov 12, 2024

Eli Lilly & Co. stock underperforms Tuesday when compared to competitors - MarketWatch

Nov 12, 2024
pulisher
Nov 12, 2024

Recode Ventures, in Partnership with Lilly, Launches Recode Edge, a Multi-Million Dollar Program to Enable AI-Powered Healthcare Innovations - PR.com

Nov 12, 2024
pulisher
Nov 12, 2024

Third Rock-backed Trace uses $101M series A to go after same ALS target as Lilly - Fierce Biotech

Nov 12, 2024
pulisher
Nov 11, 2024

Eli Lilly Falls More Than 10% In A Month: Buy, Sell Or Hold The Stock? - Barchart

Nov 11, 2024
pulisher
Nov 11, 2024

Eli Lilly Falls More Than 10% in a Month: Buy, Sell or Hold the Stock? - Yahoo Finance

Nov 11, 2024
pulisher
Nov 11, 2024

Eli Lilly buys another 31 acres in Kenosha County - BizTimes Milwaukee

Nov 11, 2024
drug_manufacturers_general NVO
$99.81
price down icon 1.90%
drug_manufacturers_general JNJ
$154.77
price up icon 0.50%
$166.28
price up icon 0.78%
drug_manufacturers_general MRK
$96.56
price up icon 0.26%
drug_manufacturers_general NVS
$103.04
price down icon 0.02%
자본화:     |  볼륨(24시간):